Bryan Johnson· Author
Studies on plasmid VEGF gene therapy have shown no significant systemic increases, despite improving heart perfusion in patients with advanced coronary artery disease. Even viral vectors—currently too risky for longevity applications due to high complications—barely provide a 3-fold increase.